Themes / Group
Building · established relationshipLatest completed snapshot · Jul 14 · 18:03 ET

MARKET-DISCOVERED GROUP

Gene Therapies

THE TRADER READCLNN dominates an otherwise mixed group path

5 of 8 measured SPY-adjusted paths align to the upside across 3.7 effective names. Capital-flow agreement is 18%, so the basket is not yet clean. No verified headline preceded the measured move.

Price breadth7 up · 1 down+0.5% median path versus SPY
Capital-flow alignment18%Price breadth is not yet confirmed by flow
Activity nowNormalActivity score 40/100 · lift 1.0×
Evidence depth2 episodesLow sample—context, not a validated playbook
EVIDENCE CLOCK

What happened, in timestamp order

4 timed events · 15:25–15:55 ET
TIMING READNo verified timestamped headline was found within 24 hours of the first measured price move in the available common-bar window. The move currently reads as market-led or unexplained.
  1. 5-minute inferenceCLNN registered the first material downside path

    -2.56% session path at the threshold · CLNN

  2. 5-minute inferencePACB registered a material upside path

    +0.99% session path at the threshold · PACB

  3. 5-minute inferenceBCDA registered a material upside path

    +0.90% session path at the threshold · BCDA

  4. 5-minute inferenceDNA registered a material upside path

    +0.92% session path at the threshold · DNA

2 earlier filing context receipts

MON, FEB 23ABCL filing documented shared operating contextproduct pipeline / R&D affecting expense · date precision only

THU, MAY 14BCDA filing documented shared operating contextproduct pipeline / R&D affecting expense · date precision only

Headline times and retained activity confirmations are point-in-time evidence. Price order is inferred from aligned 5-minute bars. Filing evidence has date precision only and is context, not an intraday catalyst claim.
THEME CONSTRUCTION

Broad move or one-stock disguise?

SPY-adjusted 5m paths

Observed movement is concentrated across 3.7 effective names. CLNN represents 45.9% of absolute path energy; 5 of 8 members align with the up relative path.

ConstructionConcentrated45.9% from the largest path
Effective names3.7 / 8Movement diversity after concentration
Direction breadth5/8 alignedupside relative path · 2 counter-moving
Largest moverCLNN 45.9%61.6% from the top two paths
CLNN45.9%Dominant mover · path -3.63% · basket -0.45pp
PACB15.7%Aligned contributor · path +1.24% · basket +0.15pp
BCDA10.3%Aligned contributor · path +0.82% · basket +0.10pp
ABCL10.1%Aligned contributor · path +0.80% · basket +0.10pp
DNA7.3%Aligned contributor · path +0.58% · basket +0.07pp
TEM6.6%Aligned contributor · path +0.52% · basket +0.07pp
RXRX2.9%Counter-move · path -0.23% · basket -0.03pp
VERU1.2%Flat / inactive path · path +0.09% · basket +0.01pp
Top six names by movement share are shown. Movement share measures absolute 5-minute path energy; signed basket contribution is equal-weight. Neither is a portfolio weight or causal attribution.

01 · WHAT IS HAPPENING

The move, the flow and who is driving it

Price breadth, unusual activity and signed capital flow are separate observations
HOW THE PRICE MOVE SPREAD

Observed session sequence

5-minute bars · inferred
  1. CLNN moved lower firstFirst member to clear the material path threshold · path -2.56%
  2. PACB registered a material higher path0m after the first price move · path +0.99%
  3. BCDA registered a material higher path0m after the first price move · path +0.90%
  4. DNA registered a material higher path0m after the first price move · path +0.92%
  5. RXRX registered a material lower path0m after the first price move · path -0.72%
  6. TEM registered a material higher path10m after the first price move · path +0.56%

Sequence inferred from aligned 5-minute price paths; it is not a causal ordering.

RELATIVE CO-MOVEMENT

How the members are behaving together

SPY-adjusted
Aug 25 · 15:25 ETMove visible 15:55 ETAug 25 · 15:55 ET
Group median +0.55%Strongest relative path PACBWeakest relative path CLNN

Observed member paths adjusted against SPY. The dashed marker shows when the median move first cleared a material threshold; shading marks the latest 20% of the observed window.

02 · WHY IT MATTERS

Why now and where the move could travel

Context and lead/lag links are evidence, not proof of causation or a forecast
WHY NOW

Verified recent context

0 items

No verified recent catalyst is attached to this move. The relationship may be market-led rather than news-led.

WHY THIS GROUP EXISTS

Shared filing context

8/8 members covered

Moderate filing support: the strongest shared 10-Q/K outlook is operating setup (near-term outlook) across ABCL, CLNN, DNA, PACB, RXRX, TEM, VERU.

product pipeline / R&D affecting expense

“Research and development expenses decreased to approximately $1.2 million in the three months ended March 31, 2026 as compared to approximately $1.5 million in the three months ended March 31, 2025, primarily due to closeout of the CardiAMP Heart Failure Trial, partially offset by early enrollment in the CardiAMP Heart Failure II Trial and regulatory activities to advance CardiAMP in Japan.”

BCDA 10-Q · 2026-05-15
restructuring affecting expense

“Through December 31, 2025, there have been no such impairment losses. (j) Clinical Trial Accruals As part of the process of preparing our consolidated financial statements, we are required to estimate our expenses resulting from our obligations under contracts with vendors and consultants and clinical site agreements in connection with conducting clinical trials.”

BCDA 10-K · 2026-03-24
restructuring

“If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, exclusion from participation in government healthcare programs, such as Medicare and Medicaid and imprisonment, damages, fines and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.”

BCDA 10-K · 2026-03-24
CONFIRMATION NETWORK

Outsiders and cross-asset links

0 outsiders confirming

No qualified cross-asset lead/lag link is available for this group.

Filing-linked outsiders test whether the move is spreading beyond the established cohort.

PRTANot confirming

RXRX · text peer

RVTYNot confirming

PACB · text peer

WGSNot confirming

PACB · text peer

TWSTNot confirming

PACB · text peer

03 · WHO IS IN IT

Member participation

Unusual activity and daily price direction are shown separately
BCDARXRXTEMABCLDNAPACBVERUCLNN

5/8 active7 rising · 1 falling

MemberUnusual activityToday's moveRead now
BCDABioCardia, Inc.
Most unusual · 100/100
+7.5%
Aligned path contributorActive in 14.3% of observed group sessions
RXRXRecursion Pharmaceuticals, Inc.
Elevated · 62/100
+9.7%
Counter-move / dispersionActive in 28.6% of observed group sessions
TEMTempus AI, Inc.
Elevated · 42/100
+3.8%
Aligned price + flowActive in 0% of observed group sessions
ABCLAbCellera Biologics Inc.
Elevated · 31/100
+17.8%
Aligned price + flowActive in 0% of observed group sessions
DNAGinkgo Bioworks Holdings, Inc.
Elevated · 27/100
+11.1%
Aligned price + flowActive in 14.3% of observed group sessions
PACBPacific Biosciences of Californ
Quiet · 22/100
+18.8%
Watch / laggardActive in 0% of observed group sessions
VERUVeru Inc.
Quiet · 12/100
+4.4%
Watch / laggardActive in 0% of observed group sessions
CLNNClene Inc.
Quiet · 10/100
-0.1%
Watch / laggardActive in 42.9% of observed group sessions
View exact member values
TICKERCompanyRole nowTodayObserved historyTrader interpretation
BCDABioCardia, Inc.Most unusual+7.5%14.3% of 7 sessionsMost unusual activity in this snapshot; performance direction may differ.
RXRXRecursion Pharmaceuticals, Inc.Participating+9.7%28.6% of 7 sessionsPrice participation with accumulating signed flow.
TEMTempus AI, Inc.Participating+3.8%0% of 7 sessionsPrice participation with accumulating signed flow.
ABCLAbCellera Biologics Inc.Participating+17.8%0% of 7 sessionsPrice participation with accumulating signed flow.
DNAGinkgo Bioworks Holdings, Inc.Participating+11.1%14.3% of 7 sessionsPrice participation with distributing signed flow.
PACBPacific Biosciences of CalifornQuiet / lagging+18.8%0% of 7 sessionsNot participating yet; a breadth test or a genuine divergence.
VERUVeru Inc.Quiet / lagging+4.4%0% of 7 sessionsNot participating yet; a breadth test or a genuine divergence.
CLNNClene Inc.Quiet / lagging-0.1%42.9% of 7 sessionsNot participating yet; a breadth test or a genuine divergence.

04 · HAS THIS HAPPENED BEFORE

Identity history versus measured outcomes

Structural recurrence is not the same as a validated trading outcome
POINT-IN-TIME LIVE OUTCOMES

Live outcome ledger collecting

0/0 events completed

No completed point-in-time outcome is available yet. New live confirmations are now retained with their exact observation timestamp; statistics appear only after the corresponding candles complete.

Only point-in-time live watcher observations and conservative same-day EOD observations are included. Later backfills and replay runs are excluded.
Low structural sample

Only 2 completed episodes across 7 active sessions; treat history as context, not a validated playbook. These episode counts describe recurrence; the outcome ledger above is the only forward-performance evidence.

Structural support59 daysHow often the cohort identity was observed
Completed episodes2Separate periods of broad group activity
Active sessions7Completed session observations, not trades
2026-07-071 active session100% composition consistency through the episode
2026-06-25 → 2026-07-026 active sessionsNo name was active through every recorded session
MEMBER CONSISTENCY IN OBSERVED ACTIVE SESSIONS
CLNN42.9% · 2 episodes
RXRX28.6% · 2 episodes
BCDA14.3% · 1 episode
DNA14.3% · 1 episode
ABCL0% · 0 episodes
PACB0% · 0 episodes
TEM0% · 0 episodes
VERU0% · 0 episodes